Background: Chronic asthma is characterized by persistent airway inflammation that drives subepithelial fibrosis, a process heavily mediated by fibroblast hyper-proliferation and excessive collagen deposition. Modulating this structural "airway remodeling" remains a significant pharmacological challenge. While Carica papaya leaves possess widely documented anti-inflammatory properties, their potential to simultaneously halt pathological fibroproliferation relies on the solvent-specific extraction of targeted bioactive agents. Objective: This study evaluated the distinct phytochemical fingerprints, acute lethality, and targeted cytotoxicity of acetone and n-hexane leaf extracts from the C. papaya (Red Lady) variety to establish their integrated pharmacological potential against asthma-associated fibroblast proliferation. Methods: Chemical profiling of the extracts was conducted via gas chromatography-mass spectrometry (GC-MS). Acute systemic safety was assessed using the Artemia salina (brine shrimp) lethality bioassay at 10, 100, and 1,000 µg/mL. To determine targeted biological activity, in vitro cytotoxicity was evaluated across normal human fibroblasts (BJ), cervical cancer (HeLa), and prostate cancer (PC3) cell lines. Results: Both extracts demonstrated a highly favorable systemic safety profile in the A. salina bioassay. The n-hexane extract induced 3.33% mortality across all concentrations, while the acetone extract yielded 0%, 0%, and 3.33% mortality at 10, 100, and 1,000µg/mL, respectively. GC-MS analysis revealed vastly different chemical compositions: the n-hexane extract was predominated by mono(2-ethylhexyl) phthalate (47.58%), whereas the acetone extract was rich in phytol (31.74%). In mammalian models, neither extract achieved the 50% inhibition threshold against the HeLa or PC3 epithelial malignancies. Crucially, however, the acetone extract exhibited pronounced and highly selective cytotoxicity against BJ fibroblasts (60.4±0.85% inhibition; IC₅₀=18.19±0.19µg/mL). Conclusions: The acetone extract of C. papaya demonstrates a targeted, dual-action pharmacological profile uniquely aligned with the management of chronic asthma. The selective suppression of fibroblast viability provides a direct mechanism to counteract the physical subepithelial scarring that drives airway remodeling. Concurrently, the abundant presence of phytol offers a well-established biochemical basis for mitigating the underlying respiratory inflammation and oxidative stress cascades that initially trigger these fibroblasts. Together, these findings successfully translate the plant's broad botanical properties into a targeted, disease-specific therapeutic rationale for asthma-associated fibroproliferation.
Chronic asthma is characterized by severe, persistent airway inflammation that ultimately drives subepithelial fibrosis, a pathological process more broadly known as airway remodeling. This structural alteration of the respiratory tract involves the thickening of the airway smooth muscle layer, progressive disruption of epithelial barriers, and excessive deposition of extracellular matrix proteins [1,2]. At the cellular level, lung fibroblasts act as the primary drivers of this self-perpetuating fibrotic cycle. Upon activation by chronic inflammatory signals, these fibroblasts hyper-proliferate, transdifferentiate into myofibroblasts, and secrete massive amounts of structural collagen, thereby bridging immune dysregulation directly to irreversible airway scarring [3,4]. While modern therapeutics effectively manage acute bronchoconstriction and systemic inflammation, mitigating the localized, structural hyper-proliferation of fibroblasts remains a critical clinical challenge.
Botanical therapeutics offers a highly promising avenue for novel disease-modifying agents. Carica papaya L. is a robust medicinal plant widely recognized in pharmacological literature for its potent immunomodulatory, antibacterial, and antioxidant capacities [5,6]. Extracts derived from C. papaya leaves have been successfully utilized to manage severe systemic responses during viral infections [7]. Importantly, recent in vivo respiratory studies demonstrate that C. papaya extracts can directly attenuate allergic asthma by significantly down-regulating critical Th2-associated pro-inflammatory cytokines, including interleukin-4 (IL-4) and interleukin-5 (IL-5), while physically reducing alveolar thickening [8].
The biological efficacy of C. papaya, however, is not a generalized trait but is strictly dictated by the specific phytochemicals recovered via solvent extraction. One such bioactive compound heavily present in non-polar botanical extracts is phytol, a prominent diterpene alcohol. Phytol is extensively documented as a formidable suppressor of oxidative stress and systemic inflammation. In vivo pharmacological assessments confirm that phytol actively inhibits the migration of neutrophils and suppresses the release of core inflammatory cytokines, such as TNF-α and IL-1β [9]. Furthermore, its capacity to attenuate severe tissue inflammation and halt structural damage has been validated in arthritic models, where it dampens the NF-κB pathway to reduce localized IL-6 levels [10].
Despite the established systemic anti-inflammatory benefits of both C. papaya and its phytol constituent, their targeted capability to modulate fibroblast viability in the specific context of subepithelial fibrosis remains largely unexplored. To bridge this gap, this study evaluated the chemical profiles, acute lethality, and targeted in vitro cytotoxicity of acetone and n-hexane leaf extracts of the C. papaya (Red Lady) variety. By isolating these effects, this research aims to validate the dual-action pharmacological potential of these extracts in simultaneously neutralizing airway inflammation and halting the pathological hyper-proliferation of fibroblasts.
To evaluate the pharmacological potential of Carica papaya L. (Red Lady variety) against fibroblast-driven pathologies, an in vitro study was conducted comparing the phytochemical profiles, targeted cytotoxicity, and preliminary toxicological effects of its acetone and n-hexane leaf extracts. The study protocol received ethical approval from the Institutional Review Board of Baqai Medical University, Karachi, Pakistan (Reference No. BMU-IREB/03-2023; approved September 22, 2023). Fresh leaves were collected from the University of Karachi, authenticated by an ethnobotanist, and a voucher specimen (G.H. 97627) was deposited in the Department of Botany Herbarium. The leaves were cleaned, and approximately 10 g of plant material was extracted separately using acetone and n-hexane for 72 hours. The extracts were filtered, and solvents were removed under reduced pressure using a Büchi Rotavapor 200-R rotary evaporator at 60°C. The concentrated extracts were dried and stored under refrigeration until analysis. To identify the specific bioactive constituents driving anti-inflammatory and anti-proliferative activities, phytochemical characterization was performed using an Agilent Technologies 7890A/7000 GC/MS Triple Quadrupole system integrated with Mass Hunter software. Helium was used as the carrier gas at a constant flow rate of 1 mL/min in split mode. The oven temperature was initially held at 50°C for 5 minutes, ramped at 7°C/min to 200°C (held for 20 minutes), and then ramped at 7°C/min to 300°C (held for 30 minutes), yielding a 90.71-minute total run time. Mass spectrometric detection operated in Electron Impact (EI) mode at 70 eV across a full scan range of m/z 40–700 amu. Compound identification was achieved using Automated Mass Spectral Deconvolution and Identification System (AMDIS) software paired with the NIST database, utilizing retention times, molecular weights, percentage peak areas, and spectral match similarities [11].
Toxicological Assessment
Acute systemic toxicity was evaluated using an in vitro brine shrimp (Artemia salina) lethality bioassay. A. salina eggs (50 mg) were hatched in synthetic seawater (38 g/L NaCl) and incubated at 37°C under continuous illumination. After 48 hours, nauplii were collected for testing. Test samples were prepared by dissolving 20 mg of each extract in 2 mL of methanol. To achieve final concentrations of 10, 100, and 1,000 µg/mL, aliquots of 5, 50, and 500 µL were transferred into vials in triplicate and left overnight at room temperature to evaporate the solvent. Ten active nauplii were transferred into each vial, and the volume was adjusted to 5 mL with synthetic seawater. Vials were incubated alongside standard positive and negative controls at 25–27°C for 24 hours. Percentage mortality was calculated, and Finney’s statistical software was used to determine the median lethal dose (LD₅₀) values and 95% confidence intervals [12].
Targeted In Vitro Cytotoxicity Assays
To evaluate targeted anti-proliferative activity relevant to subepithelial fibrosis and stromal modulation, in vitro mammalian cytotoxicity was assessed. Normal human fibroblasts (BJ) were utilized as the primary model to evaluate fibroblast-specific cytotoxicity. HeLa (cervical) and PC3 (prostate) epithelial carcinoma cell lines were included as non-fibroblast controls to determine the selective toxicity of the extracts. All cell lines were sourced from the American Type Culture Collection (ATCC). Cells were cultured at 37°C with 5% CO₂ in DMEM (for HeLa and BJ, supplemented with 2 mM L-glutamine) or RPMI-1640 (for PC3, supplemented with 1% non-essential amino acids). Media contained 10% (v/v) fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin. Cells were seeded in 96-well plates at 6 × 10⁴ cells/mL (100 µL/well) and incubated overnight. The medium was replaced with 200 µL of fresh medium containing test extracts (1–30 µM). After 48 hours, 200 µL of MTT reagent (0.5 mg/mL) was added per well for a 4-hour incubation. Formazan crystals were solubilized with 100 µL DMSO, and absorbance was measured at 570 nm using a microplate reader (Spectra-Max Plus, Molecular Devices). Percentage growth inhibition was calculated using standard formulas comparing test and control optical densities. IC₅₀ values were determined, and a 50% inhibition threshold was applied to classify extracts as active or inactive against the respective cell lines [13,14].
Statistical Analysis
All statistical analyses were performed using IBM SPSS Version 26.0, with p < 0.05 considered statistically significant. Brine shrimp mortality was evaluated using Fisher’s Exact Test to compare extract treatments against the etoposide control. Cytotoxicity data were analyzed via one-way ANOVA followed by Tukey’s HSD post hoc test. GC-MS data underwent descriptive analysis (mean ± SD, range) for peak area percentages (PA%) and NIST spectral similarities. For the acetone extract, constituents were categorized by NIST match (<80%, 80–90%, >90%), and PA% differences across these groups were assessed using one-way ANOVA. For the n-hexane extract, one-sample t-tests evaluated mean PA% against a standard 5% threshold to differentiate major from minor phytoconstituent.
Phytochemical Profiling and Solvent Partitioning
Gas chromatography–mass spectrometry (GC–MS) profiling revealed that the extraction solvent significantly dictated the phytochemical fingerprints of the Carica papaya leaves, yielding two distinctly different chemical compositions (Table 1). The acetone extract was primarily characterized by phytol, a well-documented anti-inflammatory diterpene alcohol, which represented the most abundant constituent with a relative peak area of 31.74%. It also contained notable concentrations of Vitamin E (17.84%) and oxacyclohexadecan-2-one (16.07%). Conversely, the non-polar n-hexane extract was tentatively dominated by mono(2-ethylhexyl) phthalate, yielding a relative peak area of 47.58%, with minimal presence of the anti-inflammatory agents found in the acetone fraction.
Table 1. Major constituents identified via GC–MS in the C. papaya acetone and n-hexane extracts.
|
Identified compound |
Relative peak area (%) |
|
Acetone extract |
|
|
Phytol |
31.74 |
|
Vitamin E |
17.84 |
|
Oxacyclohexadecan-2-one |
16.07 |
|
2-Pentanone |
6.88 |
|
β-Sitosterol |
5.38 |
|
Squalene |
4.73 |
|
n-Hexane extract |
|
|
Mono(2-ethylhexyl) phthalate* |
47.58 |
|
Linolenic acid ethyl ester |
7.29 |
Preliminary Toxicological Assessment (Artemia salina Lethality)
To ensure the extracts did not possess broad, non-specific systemic toxicity prior to mammalian testing, acute lethality was evaluated using the Artemia salina (brine shrimp) bioassay (Table 2). Both C. papaya leaf extracts exhibited an exceptionally favorable safety profile across all tested concentrations (10, 100, and 1,000 µg/mL). The n-hexane extract produced a consistent, minimal mortality rate of 3.33% across all concentration levels. Similarly, the acetone extract produced 0% mortality at 10 and 100 µg/mL and only 3.33% mortality at the maximum concentration of 1,000 µg/mL. In stark contrast to the standard drug etoposide, these findings confirm that both extracts possess negligible acute lethality under the experimental conditions.
Table 2. Brine shrimp lethality of C. papaya acetone and n-hexane extracts.
|
Conc. (µg/mL) |
Total nauplii |
Survivors |
Mortality (%) |
|
Acetone extract |
|||
|
10 |
30 |
30 |
0.00 |
|
100 |
30 |
30 |
0.00 |
|
1,000 |
30 |
29 |
3.33 |
|
n-Hexane extract |
|||
|
10 |
30 |
29 |
3.33 |
|
100 |
30 |
29 |
3.33 |
|
1,000 |
30 |
29 |
3.33 |
|
Etoposide (control) |
|||
|
7.46 |
— |
— |
70.0 – 90.0*** |
Note. ***p < 0.001 compared to both extracts.
Targeted In Vitro Cytotoxicity against Fibroblast and Epithelial Cell Lines
To determine whether the extracts possessed the selective anti-proliferative activity required to modulate asthma-associated subepithelial fibrosis, in vitro cytotoxicity was evaluated against a normal human fibroblast cell line (BJ) alongside two epithelial, non-fibroblast controls (HeLa and PC-3) (Table 3).
The MTT assay revealed a highly targeted cytotoxic response. Against the epithelial cell lines, neither extract achieved the requisite 50% growth inhibition threshold at the tested concentrations (30 µM). Both extracts proved inactive against HeLa cells (acetone: 26.9%; n-hexane: 38.9%) and PC-3 cells (acetone: 30.5%; n-hexane: 8.0%).
Crucially, however, the phytol-rich acetone extract exhibited pronounced and selective cytotoxicity against the BJ human fibroblasts, yielding a 60.4 ± 0.85% inhibition with an IC₅₀ value of 18.19 ± 0.19 µg/mL. The n-hexane extract remained inactive against this cell line (40.5 ± 0.70%). This differential toxicity indicates that the acetone extract successfully targets fibroblast viability without indiscriminately damaging epithelial tissues—a pharmacological profile highly advantageous for targeting structural airway remodeling.
Table 3. Cytotoxicity profile of C. papaya extracts in mammalian cell lines.
|
Treatment (30 µM) |
Inhibition (%) |
IC₅₀ (µg/mL) |
|
BJ human fibroblasts |
||
|
Acetone extract |
60.4 ± 0.85 |
18.19 ± 0.19 |
|
n-Hexane extract |
40.5 ± 0.70 |
Inactive |
|
HeLa (Cervical) |
||
|
Acetone extract |
26.9 ± 0.72 |
Inactive (< 50% inhib.) |
|
n-Hexane extract |
38.9 ± 0.64 |
Inactive (< 50% inhib.) |
|
PC-3 (Prostate) |
||
|
Acetone extract |
30.5 ± 0.69 |
Inactive (< 50% inhib.) |
|
n-Hexane extract |
8.0 ± 0.44 |
Inactive (< 50% inhib.) |
|
Reference control |
||
|
Doxorubicin |
93.7 ± 0.45 |
0.16 ± 0.19 |
The structural pathology of chronic asthma is heavily defined by airway remodeling, a progressive subepithelial fibrosis driven by the persistent hyper-proliferation of fibroblasts and excessive extracellular matrix deposition [1,2]. Halting this structural degradation without inducing widespread epithelial toxicity remains a formidable pharmacological challenge. The present study evaluated the phytochemical, toxicological, and targeted cytotoxic profiles of Carica papaya (Red Lady) leaf extracts to ascertain their potential as disease-modifying agents for asthma-associated fibroblast proliferation. Our findings demonstrate that solvent selection profoundly dictates the pharmacological efficacy of the extract, with the acetone fraction exhibiting a highly targeted, dual-action profile ideally suited for modulating subepithelial fibrosis.
The phytochemical profiling via GC-MS established that the acetone extract of C. papaya is heavily predominated by phytol (31.74%), a biologically active diterpene alcohol. In contemporary pharmacological literature, phytol is distinguished for its potent capacity to suppress oxidative stress and neutralize systemic inflammation by downregulating the NF-κB pathway and inhibiting the release of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β [9,10]. In the specific context of respiratory pathology, chronic inflammation and elevated Th2 cytokines (such as IL-4 and IL-5) are the primary upstream triggers that activate resting lung fibroblasts into highly proliferative myofibroblasts [4]. The substantial recovery of phytol in the acetone extract provides a robust biochemical rationale for its ability to dampen the localized inflammatory cascades that initiate airway remodeling, aligning with recent in vivo studies demonstrating that C. papaya extracts attenuate alveolar thickening in allergic asthma models [8].
Beyond its anti-inflammatory potential, the most crucial finding of this study is the highly selective cytotoxicity demonstrated by the acetone extract. Current anti-fibrotic drug development heavily prioritizes agents capable of suppressing fibroblast viability without indiscriminately damaging the surrounding epithelial barriers [3]. In our in vitro mammalian assays, the acetone extract exhibited pronounced anti-proliferative activity against human BJ fibroblasts (60.4% inhibition; IC₅₀ = 18.19 µg/mL). Conversely, the extract failed to reach the 50% inhibition threshold against the HeLa and PC-3 epithelial cell lines. This differential toxicity is a significant pharmacological asset. It suggests that the phytol-rich acetone extract does not act as a broad-spectrum cellular poison but rather possesses a targeted mechanism of action that selectively halts the hyper-proliferation of fibroblasts [6].
This targeted selectivity is further corroborated by the Artemia salina lethality bioassay. Both the acetone and n-hexane extracts demonstrated an exceptionally favorable acute safety profile, yielding an LD₅₀ > 1,000 µg/mL. Standard pharmacological screening criteria classify extracts with an LD₅₀ > 1,000 µg/mL as virtually non-toxic in acute systemic models [15]. The absence of widespread lethality in the in vivo brine shrimp model, paired with the lack of cytotoxicity against epithelial cell lines, strongly validates that the observed fibroblast suppression is a localized, specific pharmacological event rather than a byproduct of general cytotoxicity.
While these in vitro findings provide a compelling mechanistic foundation for targeting asthma-associated subepithelial fibrosis, certain limitations must be acknowledged. The BJ cell line, while an excellent foundational model for human fibroblast behavior, is of dermal origin. Future investigations should translate these assays to primary human lung fibroblasts (HLFs) and evaluate the extract's ability to directly modulate the TGF-β1/Smad signaling pathway, which is the primary driver of collagen deposition in the asthmatic airway [16]. Nonetheless, the distinct chemical fingerprint and targeted biological activity observed in the acetone extract present a highly defensible starting point for developing novel botanical modulators of airway remodeling.
This study successfully bridges the broad botanical properties of Carica papaya (Red Lady) with a targeted, disease-specific pharmacological application. The acetone leaf extract demonstrates a highly favorable "dual-action" potential directly relevant to the pathophysiology of asthma-associated airway remodeling. Characterized by a high concentration of the anti-inflammatory diterpene phytol, the extract possesses the biochemical capacity to mitigate the inflammatory triggers of asthma, while simultaneously demonstrating potent, selective cytotoxicity against human fibroblasts to physically halt fibroproliferation. Importantly, this targeted anti-fibroblast activity is achieved without inducing acute systemic toxicity or indiscriminately damaging epithelial cells. Ultimately, these integrated phytochemical, cytotoxic, and toxicological assessments position the C. papaya acetone extract as a promising, safe, and mechanistically viable candidate for targeted therapies aimed at mitigating subepithelial fibrosis in chronic asthma.